Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications
Brief Summary: The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perform essential activities of daily living, resulting in a loss of independence that is emotionally devastating and frequently irreversible. The most common complication of HZ in elderly persons is postherpetic neuralgia (PHN), which frequently results in disordered sleep, chronic fatigue, anxiety and severe depression. Antiviral therapy has a modest impact on the acute phase of HZ. However, it does not appear to prevent the development of PHN.

This study is a 5.5 year randomized, double-blind, placebo-controlled, efficacy trial to determine whether vaccination with live-attenuated Oka/Merck varicella-zoster decreases the incidence and/or severity of herpes zoster (HZ) and its complications in adults 60 years of age and older.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: Varicella-zoster vaccine | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Varicella-zoster vaccine; Assigned to Arm(s): Arm 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: A - Live zoster vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax, Biological: Placebo | Arm Label: B - recombinant zoster vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HZ/su vaccine | Arm Label: C - Live zoster vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax, Biological: Placebo | Arm Label: D - recombinant zoster vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: HZ/su vaccine | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): A - Live zoster vaccine, C - Live zoster vaccine | Intervention Type: BIOLOGICAL; Name: HZ/su vaccine; Assigned to Arm(s): B - recombinant zoster vaccine, D - recombinant zoster vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): A - Live zoster vaccine, C - Live zoster vaccine
C: Arm Label: Zoster vaccine group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): Zoster vaccine group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: HZ/su Lot A; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot B; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot C; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine (GSK 1437173A); Assigned to Arm(s): HZ/su Lot A, HZ/su Lot B, HZ/su Lot C

Answer: A